VALN Stock Overview
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Valneva SE Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €7.50 |
52 Week High | €17.05 |
52 Week Low | €6.58 |
Beta | 0.83 |
1 Month Change | -8.98% |
3 Month Change | -9.64% |
1 Year Change | -38.78% |
3 Year Change | -73.40% |
5 Year Change | n/a |
Change since IPO | -73.55% |
Recent News & Updates
Recent updates
Valneva seeking a partnership for next-gen COVID-19 vaccine
Sep 26Valneva shows booster effect of COVID shot against AstraZeneca vaccine
Aug 29Valneva launches up to $75M at-the-market ADS offering program
Aug 15Valneva: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love
Aug 08Valneva agrees to cut COVID vaccine supplies to EU
Jul 20Shareholder Returns
VALN | US Biotechs | US Market | |
---|---|---|---|
7D | 0.7% | 3.9% | 3.3% |
1Y | -38.8% | 3.4% | 25.8% |
Return vs Industry: VALN underperformed the US Biotechs industry which returned 3.8% over the past year.
Return vs Market: VALN underperformed the US Market which returned 25.1% over the past year.
Price Volatility
VALN volatility | |
---|---|
VALN Average Weekly Movement | 8.2% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VALN has not had significant price volatility in the past 3 months.
Volatility Over Time: VALN's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 676 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
VALN fundamental statistics | |
---|---|
Market cap | US$509.95m |
Earnings (TTM) | -US$109.10m |
Revenue (TTM) | US$165.34m |
3.1x
P/S Ratio-4.7x
P/E RatioIs VALN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VALN income statement (TTM) | |
---|---|
Revenue | €153.71m |
Cost of Revenue | €160.77m |
Gross Profit | -€7.06m |
Other Expenses | €94.37m |
Earnings | -€101.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 13, 2024
Earnings per share (EPS) | -0.73 |
Gross Margin | -4.59% |
Net Profit Margin | -65.99% |
Debt/Equity Ratio | 137.9% |
How did VALN perform over the long term?
See historical performance and comparison